Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACH-0143422 + ACH-0143102 in treatment-naive genotype 1 chronic hepatitis C
ACTRN12615000390583Phase 2Withdrawn
- Sponsor
- Achillion Pharmaceuticals
- Start
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ACH-3422 and odalasvir in hepatitis C virus infection (7 cohorts), sponsored by Achillion Pharmaceuticals. Primary endpoints: Safety and SVR12. Planned start Jun 2015; status: withdrawn.
02
Drugs
ACH-3422odalasvir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on ACTRN12615000390583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615000390583.